These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25856305)

  • 21. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.
    Puri A; Kramer-Marek G; Campbell-Massa R; Yavlovich A; Tele SC; Lee SB; Clogston JD; Patri AK; Blumenthal R; Capala J
    J Liposome Res; 2008; 18(4):293-307. PubMed ID: 18937120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Native silica nanoparticles are powerful membrane disruptors.
    Alkhammash HI; Li N; Berthier R; de Planque MR
    Phys Chem Chem Phys; 2015 Jun; 17(24):15547-60. PubMed ID: 25623776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
    Ranpise NS; Korabu SS; Ghodake VN
    Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
    Battistini L; Burreddu P; Sartori A; Arosio D; Manzoni L; Paduano L; D'Errico G; Sala R; Reia L; Bonomini S; Rassu G; Zanardi F
    Mol Pharm; 2014 Jul; 11(7):2280-93. PubMed ID: 24819754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
    Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smart IR780 Theranostic Nanocarrier for Tumor-Specific Therapy: Hyperthermia-Mediated Bubble-Generating and Folate-Targeted Liposomes.
    Guo F; Yu M; Wang J; Tan F; Li N
    ACS Appl Mater Interfaces; 2015 Sep; 7(37):20556-67. PubMed ID: 26322900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
    Cheng X; Lee RJ
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and characterization of mTHPC-loaded solid lipid nanoparticles for photodynamic therapy.
    Navarro FP; Creusat G; Frochot C; Moussaron A; Verhille M; Vanderesse R; Thomann JS; Boisseau P; Texier I; Couffin AC; Barberi-Heyob M
    J Photochem Photobiol B; 2014 Jan; 130():161-9. PubMed ID: 24333764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
    Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
    J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel nanoliposomal delivery system for polydatin: preparation, characterization, and in vivo evaluation.
    Wang X; Guan Q; Chen W; Hu X; Li L
    Drug Des Devel Ther; 2015; 9():1805-13. PubMed ID: 25848217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisolvent precipitation of lipid nanoparticles in microfluidic systems - A comparative study.
    Riewe J; Erfle P; Melzig S; Kwade A; Dietzel A; Bunjes H
    Int J Pharm; 2020 Apr; 579():119167. PubMed ID: 32087265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPIN: rapid synthesis, purification, and concentration of small drug-loaded liposomes.
    Roberts SA; Parikh N; Blower RJ; Agrawal N
    J Liposome Res; 2018 Dec; 28(4):331-340. PubMed ID: 28920496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of liposomes: a novel application of microengineered membranes--from laboratory scale to large scale.
    Laouini A; Charcosset C; Fessi H; Holdich RG; Vladisavljević GT
    Colloids Surf B Biointerfaces; 2013 Dec; 112():272-8. PubMed ID: 23999143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Simple and Improved Active Loading Method to Efficiently Encapsulate Staurosporine into Lipid-Based Nanoparticles for Enhanced Therapy of Multidrug Resistant Cancer.
    Tang WL; Chen WC; Roy A; Undzys E; Li SD
    Pharm Res; 2016 May; 33(5):1104-14. PubMed ID: 26758590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
    Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
    Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application.
    Chen M; Liu X; Fahr A
    Int J Pharm; 2011 Apr; 408(1-2):223-34. PubMed ID: 21316430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Full-cycle study on developing a novel structured micromixer and evaluating the nanoparticle products as mRNA delivery carriers.
    Na GS; Joo JU; Lee JY; Yun Y; Kaang BK; Yang JS; Kim K; Kim DP
    J Control Release; 2024 Sep; 373():161-171. PubMed ID: 38996922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oil-enriched, ultra-small nanostructured lipid carriers (usNLC): a novel delivery system based on flip-flop structure.
    Keck CM; Baisaeng N; Durand P; Prost M; Meinke MC; Müller RH
    Int J Pharm; 2014 Dec; 477(1-2):227-35. PubMed ID: 25455773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
    Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB
    J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.